NCT00961181CompletedNot Applicable
Paclitaxel Releasing Balloon in Patients Presenting With In-Stent Restenosis A Prospective, Multi-centre, Non-randomized Clinical Trial With Follow-up Investigations at 1, 6 and 12 Months
Conditions
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- Biotronik AG
- Enrollment
- 81
- Locations
- 2
- Primary Endpoint
- In-stent Late Lumen Loss
Study Overview
Brief Summary
The primary objective of this study is to evaluate the safety and efficacy of the paclitaxel releasing balloon in patients with in-stent restenosis in a coronary artery.
Detailed Description
All patients are treated with the paclitaxel releasing balloon Pantera Lux. The indication is in-stent restenosis in either bare metal stent (BMS) or drug eluting stent (DES).
Clinical follow up visits at 1, 6 and 12 months. Angiographic follow up visit at 6 months.
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Patient >/= 18 years
- •Written patient informed consent available
- •Patients with stable, unstable or documented silent angina pectoris
- •Patient eligible for percutaneous coronary intervention
- •Patient acceptable candidate for coronary artery bypass surgery
- •Patients with a single restenotic lesion in a previously stented area of a coronary artery (irrelevant whether BMS or DES related)
- •Target reference vessel diameter (visual estimation): 2 - 4 mm
- •Target lesion length (visual estimation): 8 - 28 mm
- •Target lesion stenosis (visual estimation): >/= 50% - < 100%
Exclusion Criteria
- •Left ventricular ejection fraction of < 30%
- •Visible thrombus in the target vessel visualized by angiography
- •Myocardial infarction (STEMI/NSTEMI) within 72 hours of the intended treatment. Determination of CKMB and/or troponin T or I is required.
- •Laboratory assessments to be done within 24 hours prior to intervention. Patients with CKMB and/or troponin T or I > 2 fold the upper limit of normal must not be included in the trial.
- •Patients with planned major surgery within 3 months after planned coronary intervention and/or risk of either acetylsalicylic acid of clopidogrel cessation
- •Lesion length longer than length of available treatment balloon
- •Impaired renal function (serum creatinine > 2.0mg/dl or 177 micro mol/l, determined within 72 hours prior to intervention)
- •Additional coronary lesions (restenotic or de novo) in the same vessel which requires treatment
- •Totally occluded coronary artery (Mehran classification IV and TIMI flow 0)
- •Target lesion located in vessel bifurcation
- •Previous and/or planned brachytherapy of target vessel
- •Target lesion located in left main coronary artery
- •Stroke or TIA < 6 months prior to procedure
- •Patient with signs of a cardiogenic shock
- •Patient under ongoing systemic immunosuppressive therapy with paclitaxel or agents of the -limus group (i.e. sirolimus, tacrolimus, everolimus)
- •Surgeries of any kind within 30 days prior to screening
- •Patient with bleeding diathesis in whom anticoagulation or antiplatelet medication is contraindicated
- •Known allergies to anti-platelet-, anticoagulation therapy, contrast media or paclitaxel
- •Pregnant and/or breast-feeding females or females who intend to become pregnant (pregnancy test required for females of child-bearing potential)
- •Patient with a life expectancy of less than one year
- •Patient currently enrolled in other investigational device or drug trial
- •Patient with known incompliance to medical (antiplatelet, anticoagulation) therapy
- •Patient not able or willing to adhere to follow-up visits including follow-up angiography
Outcomes
Primary Outcomes
In-stent Late Lumen Loss
Time Frame: 6 months
In-stent is defined as from proximal shoulder to distal shoulder of the dilated Pantera Lux balloon. Late lumen loss is defined as the difference between minimal luminal diameter after procedure and at 6 months, as evaluated by offline quantitative coronary angiography (QCA). Offline quantitative coronary angiography (QCA) analysis was performed by an independent core laboratory (Ulrich Dietz, MD, Deutsche Klinik für Diagnostik, Wiesbaden, Germany).
Secondary Outcomes
- In-segment Late Lumen Loss(6 months)
- Cumulative Major Adverse Cardiac Events Rate (Composite of Cardiac Death, Non-fatal Myocardial Infarction, Clinically Driven Target Lesion Revascularization, Clinically Driven Target Vessel Revascularization)(6 months)
- Cumulative MACE Rate (Composite of Cardiac Death, Non-fatal MI, Clinically Driven TLR, Clinically Driven TVR)(12 months)
- In-stent Diameter Stenosis (%DS)(6 months)
- In-segment Diameter Stenosis (%DS)(6 months)
- Binary In-stent Restenosis(6 months)
- Binary In-segment Restenosis(6 months)
- Technical Success(directly after intervention (after finalized treatment))
- Device Success(directly after intervention (after finalized treatment))
Investigators
Study Sites (2)
Loading locations...
Similar Trials
Unknown
Phase 4
Efficacy and Safety of Paclitaxel-eluting Balloon for Treatment of Lesions in Native Small Coronary ArteriesCoronary Artery DiseaseNCT01903902Gachon University Gil Medical Center1,000
Unknown
Not Applicable
Paclitaxel Eluting Balloon for SFA In-stent RestenosisIn-stent Arterial RestenosisNCT01616888University Health Network, Toronto30
Unknown
Not Applicable
A Study of Below The Knee Arteries' Stenosis or Occlusion Treated With LEGFLOW OTWPeripheral Artery DiseaseNCT02962232ZhuHai Cardionovum Medical Device Co., Ltd.172
Unknown
Not Applicable
PCB for Long De Novo Lesions of Main Coronary Arteries (D-Lesion Long Trial)Stable Angina PectorisUnstable Angina PectorisNCT03155971The People's Hospital of Liaoning Province60
Completed
Phase 2
P E P C A D II, The Paclitaxel-Eluting PTCA-Balloon Catheter in Coronary Artery Disease to Treat In-Stent RestenosesIn-Stent RestenosisNCT00393315University Hospital, Saarland120